MESUPRON (Oncology)

MESUPRON is a proprietary, first-in-class orally-administered protease inhibitor targeting pancreatic cancer and inflammatory gastrointestinal diseases.

MESUPRON presents a new, new non-cytotoxic approach to cancer therapy with several potential mechanisms of action to inhibit tumor invasion and metastasis.

MESUPRON was granted FDA Orphan Drug designation for the adjuvant treatment of pancreatic cancer.

RedHill acquired the worldwide exclusive development and commercialization rights to MESUPRON (excluding China, Hong Kong, Taiwan and Macao) for all indications from Munich-based WILEX AG in June 2014.

WILEX AG completed several clinical studies with MESUPRON for different indications, including several Phase I studies and two Phase II proof-of-concept studies. The first Phase II study in locally advanced non-metastatic pancreatic cancer and the second study in metastatic breast cancer, established its safety and tolerability profile. The Phase II studies with MESUPRON in both indications suggested activity as measured by both tumor response rate and overall survival of patients when administered in combination with first-line chemotherapeutic agents.

RedHill is also evaluating utilization of MESUPRON in several inflammatory gastrointestinal indications.